Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials.

ABSTRACT:

Objective

To study the efficacy and safety of lasmiditan for acute treatment of migraine in patients using migraine preventive medications.

Background

While lasmiditan has been proven to be an effective acute treatment for migraine, its effectiveness has not been examined when used concurrently with migraine preventives.

Methods

SAMURAI and SPARTAN were similarly designed, double-blind, phase 3, placebo-controlled studies of patients 18 years or older with 3 to 8 migraine attacks per month. Patients were randomized to treat a migraine attack with oral lasmiditan 50 mg (SPARTAN only), 100 mg, 200 mg, or placebo. Migraine preventives were allowed as long as doses were stable for 3 months prior to screening and were unchanged during the study. Preventive medications with

SUBMITTER: Loo LS 

PROVIDER: S-EPMC6734212 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature